WHAT IS CLAIMED IS:

1. Use of a lipid composition in the manufacture of an agent for delivering nucleic acid, wherein the lipid composition comprises one or more compounds selected from the group consisting of:

Lipid Compound No.	**Product Name**
530	2-aminohexanedioic acid
595	(2S)-2-aminohexanedioic acid
625	(2R)-2-aminohexanedioic acid

or salts, hydrates, or solvates thereof.

2. The use of claim 1, wherein the nucleic acid comprises DNA or RNA, optionally, the DNA is selected from coding DNA or non-coding DNA, the RNA is selected from antisense nucleic acid, mRNA, lncRNA, or small RNA.

3. A pharmaceutical composition, comprising a lipid composition and a nucleic acid, wherein the lipid composition comprises one or more compounds selected from the group consisting of lipids 530, 595, and 625, or salts, hydrates, or solvates thereof.

4. The pharmaceutical composition of claim 3, wherein the nucleic acid is used for treating diseases.

5. The pharmaceutical composition of claim 4, wherein the nucleic acid is used for treating cancer, inflammation, fibrotic disease, autoimmune disease or autoinflammatory disease, bacterial infection, behavioral and psychiatric disorder, blood disease, chromosomal disease, congenital and hereditary disease, connective tissue disease, digestive disease, ear nose throat disease, endocrine disease, environmental disease, eye disease, female reproductive disease, fungal infection, heart disease, hereditary cancer syndrome, immune system disorder, kidney and urinary disease, lung disease, male reproductive disease, metabolic disorder, mouth

disease, musculoskeletal disease, myelodysplastic syndrome, nutritional disease, parasitic disease, skin disease, or viral infection.

6. A kit, comprising:

one or more compounds positioned in a first container, or pharmaceutically acceptable salts, hydrates, or solvates thereof, and a nucleic acid positioned in a second container, wherein the one or more compounds are selected from the group consisting of lipids 530, 595, and 625.